COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: COVID-19 patients will receive 10 ml of shalomin syrup every 6 hours for six days. Intervention 2: Control group: COVID-19 patients will be treated with placebo syr
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: COVID-19 patients who have clinical signs of COVID-19 infection such as fever, cough, sputum production, sore throat. Patients with the positive CT scan Patients with the positive RT-qPCR for corona virus 2019 Patients who declare informed consent for enrollment in this study.
Exclusion criteria
Exclusion criteria: Pregnant women (based on WHO protocol) Lactating women (based on WHO protocol) Individuals who exhibit specific allergic reactions to shallomin syrup. Patients with heart failure, kidney failure, hepatitis, hemophilia, thalassemia or leukemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization duration. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Death in hospital. Timepoint: About one week after starting the treatment. Method of measurement: vital signs.;Blood oxygen saturation. Timepoint: Every day. Method of measurement: Pulse blood oximeter.;Fever. Timepoint: Every day. Method of measurement: Oral thermometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Blood Count (CBC). Timepoint: The first and end of intervention week. Method of measurement: H one devise.;Erythrocyte sedimentation rate (ESR). Timepoint: The first and end of intervention week. Method of measurement: Sediment pipette. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMansour Amin
Ahvaz University of Medical Sciences
Outcome results
None listed